Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy

NCT00674323 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

61

Enrollment

INDUSTRY

Sponsor class

Conditions

Polypoidal Choroidal Vasculopathy

Interventions

DRUG: Verteporfin Photodynamic Therapy
DRUG: Ranibizumab

Sponsor

Novartis